Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c ; Offers Guidance

Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.65, $0.69 better than the analyst estimate of $0.96. Revenue for the quarter came in at $687.5 million versus the consensus estimate of $653.32 million.

GUIDANCE:

Neurocrine Biosciences sees FY2025 revenue of $2.5-2.55 billion, versus the consensus of $2.68 billion.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Trump on Iran: they're not going to make the kind of deal that I think is necessary
• Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities